directs the Insurance Department to compile list of prescription drugs that the Department determines to be essential for treating diabetes. The list will include price increases for said drugs. Any manufacturer of a drug that appears on the list must provide information outlined in the measure to the Department, including the drug’s price, administrative expenditures associated with the drug, profit from the drug, financial assistance received relating to the drug, wholesale acquisition cost of the drug, a history of price increases relating to the drug, the aggregate amount of rebates received relating to the drug, and the cost associated with coupons provided directly to consumers relating to the drug no later than April 1 of each year. The measure directs a manufacturer of a drug that appears on the list to submit a report to the Department describing the reasoning for any increase to the wholesale acquisition cost of the drug. The measure directs the Department to create and maintain a website showing the list and reports submitted by manufacturers.